Key result
Dabigatran outperforms warfarin for stroke prevention in patients with atrial fibrillation.
Why the study?
Effective oral anticoagulant therapy is important to prevent ischemic stroke and thromboembolic events in patients with atrial fibrillation at moderate-to-high risk for stroke, with emerging novel anticoagulants potentially overcoming limitations of vitamin K antagonists.
Does oral anticoagulant therapy (dabigatran) prevent ischemic stroke and thromboembolic events in patients with atrial fibrillation compared to warfarin?
Does oral anticoagulant therapy (dabigatran) prevent ischemic stroke and thromboembolic events in patients with atrial fibrillation compared to warfarin?
Novel oral anticoagulants like dabigatran offer superior stroke prevention compared to warfarin in patients with atrial fibrillation.
May support dabigatran over warfarin for AF stroke prevention; leaves open need for prospective randomized confirmation.
Stroke is a fundamental cause of many cardiac disorders, and formation of Blood clots or thrombi (embolus) in the arterial circulation can lead to unstable angina, myocardial infarction, or ischemic stroke. Anticoagulant therapy is extensively used with establish benefit to prevent ischemic stroke and thromboembolic events in patients with atrial fibrillation (AF). Atrial fibrillation causes a major trouble on heart patients and CVS. Risk of stroke is increase in case of AF.The main goals of Anticoagulant therapy are to improve symptoms, reduce morbidity, mortality and chances of stroke. The results of many studies emphasize the importance of effective oral anticoagulant therapy in patients with moderate-to-high risk for stroke and superiority of dabigatran, an oral direct thrombin inhibitor, over warfarin in the prevention of stroke. Novel anticoagulants in developments may overcome some of limitations of vitamin k antagonist and address their underuse and safety concerns. : Atrial Fibrillation, Cardio vascular system.
No takes yet. Share an insight, caveat, or question.
Rathore et al. (2015) conducted a review in Atrial Fibrillation. Dabigatran vs. Warfarin was evaluated on Stroke. Dabigatran, an oral direct thrombin inhibitor, demonstrated superiority over warfarin in the prevention of stroke in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: